LY3437943 · Triple GIP/GLP-1/Glucagon Agonist · Lyophilized Powder
Retatrutide is a next-generation triple receptor agonist targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. Studied in the context of metabolic syndrome, obesity-related pathways, and energy homeostasis research.
For Research Use Only · Not for Human Consumption
Retatrutide (LY3437943) is a novel unimolecular triple agonist developed for research into complex metabolic pathways. Unlike single or dual agonists, Retatrutide simultaneously engages three distinct receptor systems, making it an important compound for researchers studying overlapping metabolic signaling networks.
Prime 9 Labs supplies Retatrutide as a lyophilized powder at ≥99% purity confirmed by HPLC analysis. Each batch undergoes independent third-party testing at accredited U.S. laboratories. A batch-specific COA is included with every order.
Retatrutide represents one of the most advanced peptide compounds under investigation for metabolic research. By engaging three independent receptor pathways, researchers can study how concurrent stimulation of GIP, GLP-1, and glucagon receptors influences energy balance and substrate metabolism.
For research purposes only. Consult institutional protocols and peer-reviewed literature before use.
| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Appearance | Visual | White lyophilized powder | Conforms | PASS |
| HPLC Purity | HPLC-UV | ≥99.0% | 99.3% | PASS |
| MS Identity | LC-MS/MS | Theoretical MW ±1% | Conforms | PASS |
| Heavy Metals | ICP-MS | <10 ppm total | <3 ppm | PASS |
| Endotoxin | LAL | <5 EU/mg | <1 EU/mg | PASS |
| Sterility | USP <71> | No growth | No growth | PASS |
| Water Content | Karl Fischer | <5% | 3.1% | PASS |
Testing performed by accredited U.S. third-party laboratory. Full COA PDF available upon request.